Three new medicines have had advice published for use in conditions including a rare and fatal genetic condition affecting young children and a form of leukaemia.
The Scottish Medicines Consortium (SMC) issued the advice for atidarsagene autotemcel (Libmeldy), venetoclax (Venclyxto) and upadacitinib (Rinvoq).
Libmeldy, a highly specialised stem cell treatment given as a single dose, can be used to treat children with a rare genetic condition called metachromatic leukodystrophy (MLD).